Eli Lilly Gets FDA Approval for Zepbound to Treat Sleep Apnea, Obesity

MT Newswires Live12-21 06:07

Eli Lilly (LLY) said late Friday that the US Food and Drug Administration approved its tirzepatide product Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea and obesity.

The approval was based on results from a phase 3 trial, which showed that 42% of adults taking Zepbound and 50% of those on Zepbound with positive airway pressure therapy achieved remission or mild, non-symptomatic sleep apnea after one year, compared with 16% and 14%, respectively, for those on placebo, the company said.

The results also demonstrated an average 18% weight loss among adults taking Zepbound and 20% among those on Zepbound with positive airway pressure therapy, compared to just a 2% weight loss for those on placebo, Eli Lilly said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment